Nkarta, Inc.

Nkarta, Inc.

Biotechnology • Healthcare • South San Francisco, CA, United States • NKTX (NMS)

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

925 407 1049 1150 Veterans Boulevard, South San Francisco, CA 94080, United States

Stock Performance (90 Days)

Data through Dec 29, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
MarketBeat • Dec 27
Nkarta: Pushing Deeper And Deeper Into A Discount Vs. Their Holdings, For No Real Reason - Seeking Alpha
Seeking Alpha • Nov 22
Nkarta (NKTX) Upgraded to Buy: Here's Why - Yahoo Finance
Yahoo Finance • Apr 14
Nkarta to lay off staff, senior leadership, in bid to advance autoimmune cell therapy - BioPharma Dive
BioPharma Dive • Mar 27
$NKTX stock is up 11% today. Here's what we see in our data. - Quiver Quantitative
Quiver Quantitative • Aug 13

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Nkarta, Inc. had layoffs?
No layoff events have been recorded for Nkarta, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Nkarta, Inc. have?
Nkarta, Inc. has approximately 105 employees.
What industry is Nkarta, Inc. in?
Nkarta, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Nkarta, Inc. a publicly traded company?
Yes, Nkarta, Inc. is publicly traded under the ticker symbol NKTX on the NMS. The company has a market capitalization of approximately $0.13 billion.
Where is Nkarta, Inc. headquartered?
Nkarta, Inc. is headquartered in South San Francisco, CA, United States at 1150 Veterans Boulevard, South San Francisco, CA 94080, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.